DRUG REVINORM INFLUENCE ON THE CLINICAL CONDITION AND BIOCHEMICAL BLOOD INDICATORS OF LABORATORY ANIMALS UNDER HEAT STRESS

The aim of the study is to investigate the effect of the new drug Revinorm on the clinical condition and biochemical blood parameters of laboratory animals under experimental acute heat stress. The object of the study was the drug Revinorm, which includes active substances with antipyretic, antioxidant, antihypoxic, nootropic and hepatoprotective activity. When modeling acute heat stress, laboratory rats (n = 10) were placed in containers that were installed under direct sunlight with the main meteorological parameters – clear, temperature in the shade 37.1 °C, in the sun 43–45 °C, relative humidity 19 %, atm. pressure 759 mm Hg, UV index 8, magnetic storm level G1. When the first clinical signs of acute thermal overheating appeared, the rats in the 1st and 2nd experimental groups were given the drug Revinorm in doses of 0.4 g/kg body weight (1st experimental group) and 0.6 g/kg body weight (2nd experimental group). The rodents of the 3rd control group did not receive any treatment during hyperthermia. All animals were clinically observed, and blood was collected from 5 rats from each group 1.5 hours after the completion of the clinical part of the experiment for biochemical studies. The results of the preclinical study showed that the drug Revinorm exhibits pronounced pharmacological activity in experimental acute heat stress in laboratory rats, which is manifested by an increase in the survival rate of rodents by 40–60 %, a decrease in the clinical severity of the stress reaction and pathological changes in the biochemical para¬meters of the blood. An effective dose of Revinorm was determined on laboratory animals, amounting to 0.6 g/kg of body weight, which serves as a rationale for the stage of clinical trials of the drug on productive animals under heat stress.